Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,788 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy.
Hokimoto S, Akasaka T, Tabata N, Arima Y, Tsujita K, Sakamoto K, Kaikita K, Morita K, Kumagae N, Yamamoto E, Oniki K, Nakagawa K, Ogawa H. Hokimoto S, et al. Among authors: nakagawa k. Thromb Res. 2015 Jun;135(6):1081-6. doi: 10.1016/j.thromres.2015.03.033. Epub 2015 Apr 11. Thromb Res. 2015. PMID: 25891840
Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy.
Arima Y, Kaikita K, Ishii M, Ito M, Sueta D, Oimatsu Y, Sakamoto K, Tsujita K, Kojima S, Nakagawa K, Hokimoto S, Ogawa H. Arima Y, et al. Among authors: nakagawa k. J Thromb Haemost. 2016 Apr;14(4):850-9. doi: 10.1111/jth.13256. Epub 2016 Feb 19. J Thromb Haemost. 2016. PMID: 26773298 Free article.
Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy.
Yamamoto K, Hokimoto S, Chitose T, Morita K, Ono T, Kaikita K, Tsujita K, Abe T, Deguchi M, Miyagawa H, Saruwatari J, Sumida H, Sugiyama S, Nakagawa K, Ogawa H. Yamamoto K, et al. Among authors: nakagawa k. J Cardiol. 2011 Mar;57(2):194-201. doi: 10.1016/j.jjcc.2010.10.007. Epub 2010 Dec 17. J Cardiol. 2011. PMID: 21168310 Free article.
Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention.
Ono T, Kaikita K, Hokimoto S, Iwashita S, Yamamoto K, Miyazaki Y, Horio E, Sato K, Tsujita K, Abe T, Deguchi M, Tayama S, Sumida H, Sugiyama S, Yamabe H, Nakamura S, Nakagawa K, Ogawa H. Ono T, et al. Among authors: nakagawa k. Thromb Res. 2011 Dec;128(6):e130-6. doi: 10.1016/j.thromres.2011.07.028. Epub 2011 Aug 20. Thromb Res. 2011. PMID: 21862109
Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
Fujisue K, Sugiyama S, Ono T, Matsuzawa Y, Akiyama E, Sugamura K, Matsubara J, Kurokawa H, Kaikita K, Iwashita S, Sumida H, Hokimoto S, Oniki K, Nakagawa K, Matsui K, Ogawa H. Fujisue K, et al. Among authors: nakagawa k. Circ Cardiovasc Interv. 2013 Aug;6(4):452-9. doi: 10.1161/CIRCINTERVENTIONS.112.000278. Epub 2013 Aug 6. Circ Cardiovasc Interv. 2013. PMID: 23922147
Response to letter regarding article, "Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease".
Fujisue K, Sugiyama S, Ono T, Matsuzawa Y, Akiyama E, Sugamura K, Matsubara J, Kurokawa H, Kaikita K, Iwashita S, Sumida H, Hokimoto S, Oniki K, Nakagawa K, Matsui K, Ogawa H. Fujisue K, et al. Among authors: nakagawa k. Circ Cardiovasc Interv. 2013 Oct 1;6(5):e66. doi: 10.1161/CIRCINTERVENTIONS.113.000788. Circ Cardiovasc Interv. 2013. PMID: 24129939 No abstract available.
Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
Hokimoto S, Chitose T, Mizobe M, Akasaka T, Arima Y, Kaikita K, Iwashita S, Morita K, Miyazaki H, Oniki K, Matsui K, Nakagawa K, Ogawa H. Hokimoto S, et al. Among authors: nakagawa k. Eur J Clin Pharmacol. 2014 Jun;70(6):667-73. doi: 10.1007/s00228-014-1672-3. Epub 2014 Apr 26. Eur J Clin Pharmacol. 2014. PMID: 24763934 Clinical Trial.
4,788 results